Form 4: Pacific Biosciences Director Lucy Shapiro Granted 65,000 Stock Options

Pacific Biosciences of California, Inc. (PACB) Director Lucy Shapiro was granted 65,000 stock options with an exercise price of $1.03, vesting over one year.

Summary

• Lucy Shapiro, a Director of Pacific Biosciences of California, Inc. (PACB), was granted 65,000 stock options on June 4, 2025.
• The stock options have an exercise price of $1.03 per share.
• These options will vest monthly over a one-year period, starting July 4, 2025, or earlier upon the date of the next annual stockholders' meeting, provided Ms. Shapiro continues to serve as a director.
• The options are set to expire on June 4, 2035.
• Following this transaction, Ms. Shapiro beneficially owns 65,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive event as it aligns management's interests with shareholders, but it is a routine compensation disclosure and does not indicate significant operational or financial news.

Positives

• The grant of stock options to Director Lucy Shapiro aligns her financial interests with those of the company's shareholders, incentivizing long-term performance and value creation.
• The exercise price of $1.03 is relatively low, suggesting a potential for future upside if the company's stock price increases.

Risks

• The vesting of the stock options is contingent upon Ms. Shapiro's continued service as a director; if her service ceases before full vesting, the unvested options could be forfeited.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of an insider's equity compensation, common across all industries, including the biotechnology and genomics sector where Pacific Biosciences operates. It does not provide insights into broader industry trends or competitive dynamics.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director constitutes a related party transaction, as it involves compensation from the company to a member of its board. This is a standard and disclosed form of related party compensation.

Stakeholder Impact

• Shareholders: Potentially positive, as the option grant aligns the director's incentives with shareholder value creation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The stock options will vest monthly over the next year, contingent on Lucy Shapiro's continued service as a director.
• The options will become fully exercisable by June 4, 2026, or earlier if the next annual meeting occurs before then.

Key Dates

Keywords

Pacific Biosciences of California, PACB, Lucy Shapiro, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Biotechnology, Genomics